Analysis of reasons for Emergency Department (ED) visits and subsequent hospital admissions in patients with solid malignancies: A retrospective study from a cancer center in rural Maine.

Authors

null

Anannya Patwari

Eastern Maine Medical Center, Bangor, ME

Anannya Patwari, Vineel Bhatlapenumarthi, Courtney Brann, Jackson Waldrip, Victoria Caruso, Abigail Hatch, Adam Curtis, Catherine Chodkiewicz

Organizations

Eastern Maine Medical Center, Bangor, ME, University of New England College of Osteopathic Medicine, Biddeford, ME, Northern Light Cancer Institute, Brewer, ME, Lafayette Cancer Ctr, Brewer, ME

Research Funding

No funding received
None

Background: Reducing ED visits in patients with cancer is cost saving and is particularly relevant during the COVID pandemic. We aim to identify patterns of ED visits among various cancer patients and reduce preventable ED visits and hospital admissions. Methods: We analyzed the number of ED visits and hospital admissions that occurred in patients with breast, lung, and Gastrointestinal (GI) cancers between July12019 and October31 2020 including demographics, stage, treatment type preceding the month of ED visit, reason, time of the day, day of the week the visit occurred. Results: 308 patients had 519 ED visits, 111 breast cancer patients had 184, 102 lung cancer patients had 186 and 95 GI cancer patients had 149 ED visits. 38% had > 1 visit. 51%, (37% breast, 60% Lung and 58 % GI cancer) had stage 4 disease at the time of visit. There were no visits in the month of May 2020. 275 (53%) visits required hospital admissions, 60% of ED visits in lung cancer, 54% in GI and 46 % in breast cancer patients required hospitalization. Most common reason for ED visits in breast cancer patients was fall/injury (20%), with median age of 71 years, none were cancer/ chemotherapy induced. Among lung and GI cancer patients respiratory (24%) and GI related (24%) symptoms were the most common reasons respectively, majority were cancer/chemotherapy related. Most common symptoms requiring hospital admissions were respiratory 21%, GI 18%, cardiac 12%. 11% and 9% of ED visits were due to fall/injury and cancer related pain, of these 3.6% and 9% resulted in hospital admissions respectively. Lung and GI cancer patients were more likely to be referred to the ED from the oncologist office (23%) than breast cancer patients (11%). Conclusions: Reasons for ED visits vary by tumor types and some may be preventable. Fall/injury in breast cancer patients and cancer related pain in lung and GI cancer patients were frequent reasons for preventable ED visits. In lung and GI cancer patients, cancer/chemotherapy related respiratory, GI symptoms are felt to be less avoidable since they may be related to disease progression or presenting symptoms. We have initiated several strategies such as ‘’systematic physical therapy assessment’’ of our breast cancer patients over age 70 to reduce ED visits due to fall/injury. We are developing strategies to involve palliative care early to reduce the number of ED visits related to cancer related pain We now have “call us first campaign” to assess and intervene before going to ED since most visits occurred during working hours.

Type of cancer
Specific Symptom
Total ER Visits
Hospital Admissions
Chemo Induced
Cancer Induced
Not Cancer/chemo Related
Breast cancer
Fall Injury
37
6
0
0
37
GI
28
15
8
6
14
Cardiac
20
15
0
2
18
Lung cancer
Respiratory
45
38
1
33
11
GI
23
11
9
8
6
Cancer related pain
21
13
0
21
0
GI cancer
GI
36
23
3
31
2
Respiratory
17
10
1
9
7
Cancer related pain
17
9
0
17
0

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session B: Patient Experience; Quality, Safety, and Implementation Science; Technology and Innovation in Quality of Care

Track

Technology and Innovation in Quality of Care,Patient Experience,Quality, Safety, and Implementation Science,Cost, Value, and Policy,Health Care Access, Equity, and Disparities

Sub Track

Quality Improvement Research and Implementation Science

Citation

J Clin Oncol 39, 2021 (suppl 28; abstr 241)

DOI

10.1200/JCO.2020.39.28_suppl.241

Abstract #

241

Poster Bd #

D1

Abstract Disclosures